- In December 2024, AbbVie Clinical trial result for Epcoritamab (DuoBody CD3xCD20) is a bispecific T-cell-engaging antibody developed by AbbVie. Recent data analyses from clinical trials have shown that Epcoritamab induces durable complete responses both as a monotherapy and in combination with other treatments in patients with diffuse large B-cell lymphoma (DLBCL). In the Phase 1b/2 EPCORE NHL-2 trial, Epcoritamab combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) achieved an overall response rate (ORR) of 100% and a complete response (CR) rate of 87%. Additionally, the Phase 2 EPCORE NHL-1 trial demonstrated that 41% of patients achieved a CR, with an estimated 52% still responding after three years
- In December 2024, AbbVie Clinical trial result for Epcoritamab (DuoBody CD3xCD20) is an investigational bispecific T-cell-engaging antibody developed by AbbVie. Recent clinical trial results have shown high response rates in patients with relapsed or refractory (R/R) follicular lymphoma (FL). In the Phase 1b/2 EPCORE NHL-2 trial, Epcoritamab combined with lenalidomide and rituximab (R²) achieved an overall response rate (ORR) of 96% and a complete response (CR) rate of 87% among 111 patients with a median follow-up of over two years. These results highlight the potential benefits of Epcoritamab in treating patients with R/R FL and support its ongoing evaluation in a pivotal Phase 3 trial
- In December 2022, Yescarta (axicabtagene ciloleucel) was approved in Japan for the initial treatment of relapsed/refractory large B-cell lymphoma. This approval expands the use of Yescarta to patients who have not responded to prior treatments. Yescarta is a CAR T-cell therapy that modifies the patient’s T cells to target and destroy cancerous B cells. The approval provides a promising treatment option for patients with this aggressive form of lymphoma, offering the potential for improved outcomes by targeting cancer cells more effectively, thus helping to address a significant unmet need in oncology care
- In December 2022, Kite announced its acquisition of Tmunity Therapeutics to advance the development of next-generation CAR T-cell therapies in cancer treatment. This acquisition aims to enhance Kite’s capabilities in innovative cancer therapies, particularly focusing on improving the effectiveness and accessibility of CAR T-cell treatments. By integrating Tmunity's expertise in immunotherapy and cell-based therapies, the collaboration seeks to address challenges in solid tumor treatment and expand therapeutic options for cancer patients, offering hope for more personalized, durable, and effective treatments in oncology. This move reinforces Kite’s leadership in cancer immunotherapy
- In December 2022, Data from the ZUMA-7 study reinforced the potential of Yescarta (axicabtagene ciloleucel) as an initial treatment for relapsed or refractory large B-cell lymphoma. The study demonstrated that Yescarta, a CAR T-cell therapy, significantly improved progression-free survival compared to standard chemotherapy. These findings support the use of Yescarta as an effective first-line treatment, offering a new option for patients with aggressive lymphoma who have limited treatment alternatives. The growing body of evidence highlights the therapy’s potential to improve patient outcomes and change the treatment landscape for this challenging cancer
